GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy

Explore stories from Atlantic Canada.

SaltWire's Atlantic regional weather forecast for October 31, 2023 | SaltWire - British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepatitis B therapy.

Exclusive rights to the therapy, JNJ-3989, which Arrowhead Pharmaceuticals initially developed and licensed to Janssen in 2018, will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, it said.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

SaltWire Network /  🏆 45. in CA

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Data scarce on what green energy transition will cost Nova ScotiansExplore stories from Atlantic Canada.
Lire la suite »

Twelve dead after plane crashes in Brazil's Acre stateExplore stories from Atlantic Canada.
Lire la suite »

Data scarce on what green energy transition will cost Nova ScotiansExplore stories from Atlantic Canada.
Lire la suite »

Israel summons Russian ambassador to protest at Moscow's hosting of HamasExplore stories from Atlantic Canada.
Lire la suite »